Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1293733rdf:typepubmed:Citationlld:pubmed
pubmed-article:1293733lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1293733lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:1293733lifeskim:mentionsumls-concept:C0022322lld:lifeskim
pubmed-article:1293733lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:1293733lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:1293733lifeskim:mentionsumls-concept:C0392663lld:lifeskim
pubmed-article:1293733lifeskim:mentionsumls-concept:C1627892lld:lifeskim
pubmed-article:1293733pubmed:issue4lld:pubmed
pubmed-article:1293733pubmed:dateCreated1993-4-5lld:pubmed
pubmed-article:1293733pubmed:abstractTextTwo groups of Polynesian Wuchereria bancrofti carriers, 17 females aged 21 to 84 years and 20 males aged 26 to 57 years, in whom microfilaraemia ranged from 1 to 10,121 mf/ml and from 1 to 6,484 mf/ml, respectively, were given a supervised singledose treatment with 400 mcg/kg of ivermectin. Carriers were examined and questioned regarding their experience of adverse reactions, which were graded 0 to 3 according to severity, at 6, 12 and 24 hours and at 4 days after treatment. Biological examinations which included determination of microfilaraemia, complete blood count, liver function tests and assessment of creatinine and urea levels were performed at 4 days before and 4 days after treatment. Adverse reactions were observed in 65% of female and in 70% of male carriers; they were of grade > or = 2 in 35% of carriers in both groups. None as considered serious; they all disappeared in 24-48 hours. The main symptoms were headache, fever > or = 37.5 degrees C and myalgia in females. One male vomited 3 hours after treatment; as a result the drug was not ingested and no decrease of microfilaraemia was noted. Twelve days afterwards, he was given a second 400 mcg/kg dose, he experienced again a grade 1 reaction and his microfilaraemia fell to zero. The 37 carriers in the present study were matched with 37 other Polynesian carriers treated with a 100 mcg/kg single dose of ivermectin in previous trials for pretreatment mf density and sex: no significant difference could be found in adverse reactions between the 2 treatment groups.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1293733pubmed:languageenglld:pubmed
pubmed-article:1293733pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293733pubmed:citationSubsetIMlld:pubmed
pubmed-article:1293733pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1293733pubmed:statusMEDLINElld:pubmed
pubmed-article:1293733pubmed:monthDeclld:pubmed
pubmed-article:1293733pubmed:issn0177-2392lld:pubmed
pubmed-article:1293733pubmed:authorpubmed-author:ChanteauSSlld:pubmed
pubmed-article:1293733pubmed:authorpubmed-author:RouxJ FJFlld:pubmed
pubmed-article:1293733pubmed:authorpubmed-author:CarterJ RJRlld:pubmed
pubmed-article:1293733pubmed:authorpubmed-author:Moulia-PelatJ...lld:pubmed
pubmed-article:1293733pubmed:authorpubmed-author:GlaziouPPlld:pubmed
pubmed-article:1293733pubmed:authorpubmed-author:NguyenL NLNlld:pubmed
pubmed-article:1293733pubmed:issnTypePrintlld:pubmed
pubmed-article:1293733pubmed:volume43lld:pubmed
pubmed-article:1293733pubmed:ownerNLMlld:pubmed
pubmed-article:1293733pubmed:authorsCompleteYlld:pubmed
pubmed-article:1293733pubmed:pagination263-6lld:pubmed
pubmed-article:1293733pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:meshHeadingpubmed-meshheading:1293733-...lld:pubmed
pubmed-article:1293733pubmed:year1992lld:pubmed
pubmed-article:1293733pubmed:articleTitleResults of a safety trial on single-dose treatments with 400 mcg/kg of ivermectin in bancroftian filariasis.lld:pubmed
pubmed-article:1293733pubmed:affiliationInstitut Territorial de Recherches Medicales Louis Malardé, Papeete, Tahiti, Polynésie Francaise.lld:pubmed
pubmed-article:1293733pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1293733pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed